EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
- Details
- Category: HCV Treatment
- Published on Saturday, 21 April 2012 00:00
- Written by Keith Alcorn and Michael Carter
A real-world study of recently approved hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment discontinuations than in clinical trials, Christophe Hézode reported on behalf of the French Compassionate Use of Protease Inhibitors in Cirrhotics (CUPIC) cohort study at the 47th International Liver Congress (EASL 2012) in Barcelona on Thursday.
Web Design and Development by